The Biosimilars Forum, in partnership with the Pacific Research Institute, has released a report that shows state-by-state cost savings for the US if biosimilars were able to capture a market share of 75%. Meanwhile, the Association for Accessible Medicines has also released its complete 2021 US Generic And Biosimilar Medicines Savings Report, discouraging reducing incentives for patent challenges and early generic entry.

Amgen’s recent study on biosimilars trends has outlined the importance of US policy in the success of the biosimilars marketplace, insisting on the importance of increased competition and effective reimbursement and education policies. But with interests in innovative biologics as well as biosimilars, the company has also emphasized that pro-biosimilars policies must not stifle innovation and compromise free competition.

Benign prostatic hyperplasia treatment indoramin topped the UK’s steepest generic price rises in September with an average price that more than trebled, according to the latest figures from WaveData.

Samsung Bioepis recently broke new ground with the first US approval for a biosimilar with ophthalmic indications. But, senior vice-president and development division leader Kyung-Ah Kim tells Generics Bulletin, there remains work to be done to ensure that ophthalmic biosimilars can meet their full potential.

Amgen’s 2021 Biosimilars Trends Report predicts several imminent advancements in the biosimilars space, especially with the expected US launches of biosimilars to Humira in 2023. According to Amgen, the marketplace is poised to see further growth.

Savings achieved in the US through the use of generics and biosimilars hit a new high in 2020, reaching $338bn, according to new figures released by the AAM.

Timolol eye drops saw their prices leap in August while sildenafil’s slide saw prices cut in half, according to the latest UK generics pricing figures from WaveData.

Ivabradine, lercanidipine, donepezil and aspirin led the steepest price rises seen for UK generics in July 2021, with all of these molecules experiencing triple-digit average increases in certain presentations, according to WaveData.

Ivabradine exhibited interesting pricing dynamics in the UK in June, with the average cost of the heart failure treatment more than trebling despite the lowest offer in the market remaining stable.